RxDoctor Payments Data

Scott Matson, DO

Obstetrics & Gynecology · Tazewell, TNNPI 1306896162

Payments from drug & device makers

$1,324in general payments, 2019–2025

Across 65 payments — averaging $20.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$677
  • Pfizer$491
  • AbbVie$55
  • Merz North America, Inc.$46
  • Myovant Sciences Inc.$16
  • Novo Nordisk$14
  • plus $25 from 2 others

What the payments were for

  • Food & beverage$1,31299%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK25$677
Pfizer30$491
AbbVie4$55
Merz North America, Inc.2$46
Myovant Sciences Inc.1$16
Novo Nordisk1$14
Dysis Medical, Inc.1$13
Impel Pharmaceuticals Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,324 in reported general payments places this provider in the 55th percentile of 763 obstetrics & gynecology providers in Tennessee.

See all obstetrics & gynecology providers in Tennessee

Medicare billing

Part B allowed, 2024
$28,188
Medicare patients
18
Services billed
346

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter52$35,073
Spiriva HandihalerTiotropium Bromide50$25,969
TrulicityDulaglutide26$25,648
Breo ElliptaFluticasone/Vilanterol48$19,275
Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro20$17,548
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl895$17,527
EliquisApixaban21$15,667
MyrbetriqMirabegron17$9,820
SuboxoneBuprenorphine Hcl/Naloxone Hcl129$8,760
PremarinEstrogens, Conjugated30$7,727
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$7,151
Spiriva RespimatTiotropium Bromide12$6,357
Novolog FlexpenInsulin Aspart15$3,944
Humulin 70/30 KwikpenInsulin Nph Hum/Reg Insulin Hm13$3,938
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen130$3,856

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$677$54,348100 claims
PfizerEliquis, Premarin$491$23,39451 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 763 obstetrics & gynecology providers in Tennessee.

Other obstetrics & gynecology in Tazewell

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →